CN1457794A - New use of picrorhiza rhizome and its iridoid glycoside extract - Google Patents
New use of picrorhiza rhizome and its iridoid glycoside extract Download PDFInfo
- Publication number
- CN1457794A CN1457794A CN 02113737 CN02113737A CN1457794A CN 1457794 A CN1457794 A CN 1457794A CN 02113737 CN02113737 CN 02113737 CN 02113737 A CN02113737 A CN 02113737A CN 1457794 A CN1457794 A CN 1457794A
- Authority
- CN
- China
- Prior art keywords
- medicine
- extract
- rhizoma picrorhizae
- iridoid glycoside
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to the new use of picrorhiza rhizome and its iridoid glycoside extract. Picrorhiza rhizome or its iridoid glycoside extract may be used to prepare medicine for preventing and treating fatty liver.
Description
The present invention relates to the new medicinal usage of Rhizoma Picrorhizae and iridoid glycoside extract thereof, is the application in control fatty liver medicine of Rhizoma Picrorhizae or its iridoid glycoside extract specifically.
Rhizoma Picrorhizae is one of China's Chinese medicine.Be recorded in Tang's " Newly Revised Canon of Materia Medica " the earliest, Song's " Kaibao Bencao " also records.Dry rhizome for goatweed India Rhizoma Picrorhizae (Picrorhiza kurroa Royle ex Benth), one to dependence on import, 1960's, find congener Rhizoma Picrorhizae (PScorphulariiflora Pennell) and cultivation succedaneum as India's Rhizoma Picrorhizae in Tibet and northwestern Yunnan Province.China's pharmacopeia and ministry standard are all recorded to these two kinds of Picrorrhiza at present.No matter aspect profile and histological structure, it is all very similar still to include the chemical constituent aspect for bibliographical information India Rhizoma Picrorhizae and Rhizoma Picrorhizae.
Pharmacological research shows that the glycoside extract in the Rhizoma Picrorhizae rhizome has the various biological property controlled.As anti-hepatitis B activity, liver protection, choleretic effect, effect for reducing blood fat and antifungic action etc., but do not appear in the newspapers Rhizoma Picrorhizae or its glycoside extract have the effect of prevention and treatment fatty liver.
Pharmacological research shows that the inventor has received satisfied effect with Rhizoma Picrorhizae or prevention of its glycoside extract and treatment fatty liver, has found the reliably new purposes of Rhizoma Picrorhizae or its glycoside extract.
Along with the variation of growth in the living standard and people's dietary structure, fatty liver has now become a kind of commonly encountered diseases, frequently-occurring disease.Primary disease is common in patients such as obesity, alcoholic liver disease, hepatitis, diabetes and hyperlipidemia, has become a public health problem at present, the serious harm human beings'health.Fatty liver is that the liver fat sexually transmitted disease (STD) that causes of multiple reason becomes, and accumulates when the hepatocyte inner lipid to surpass 5% or histology when going up per unit area 1/3 above liver cell fatty degeneration, can be diagnosed as fatty liver.Fatty liver is the early stage performance of multiple liver toxicity damage, as develops as one pleases, and can form fat hepatitis and hepatic fibrosis, even liver cirrhosis.Therefore Prevention and Management of Fatty Liver is very important to the development that prevents chronic hepatopathy, yet still lacking at present can effective lipotropic medicine, and can prevent effectively that the blood lipid-lowering medicine commonly used of curing hyperlipemia may not be useful to Prevention and Management of Fatty Liver, so be necessary to carry out fatty liver prevention drug research.
Therefore, purpose of the present invention just provides Rhizoma Picrorhizae or the application of its glycoside extract in the lipotropic medicine of preparation.Rhizoma Picrorhizae can be independent Rhizoma Picrorhizae raw material when the lipotropic medicine of preparation, also can Rhizoma Picrorhizae or its glycoside extract can also be prepared into compound preparation with other drug with its extract picrorhiza iridoid glycoside separately as raw material.
Extract of picrorhiza iridoid glycoside preparation technology: get a certain amount of medical material, add 80%EtOH, twice of reflux, extract.Each 8 times of amounts, merge extractive liquid, is concentrated into certain volume.With a certain amount of ethyl acetate and alcohol mixeding liquid (8: 2) extraction, extract is concentrated into dried, with Me
2CO washs extracting, and acetone solution is concentrated into dried, promptly.
Embodiment 1
The preventive and therapeutic effect of the Animal fat liver that extract of picrorhiza iridoid glycoside causes high lipid food
70 of male wistar rats, body weight 180～230g is divided into two groups at random, and 10 of first treated animals are normal group, give normal feedstuff; All the other animals are second group, give high lipid food after continuous 60 days, put to death wherein 10, do the hepatic pathology section, determine that the fatty liver model is set up after, be divided into following 5 groups at random: fatty liver model control group: give high lipid food continuously; Non-processed group: animal changes the food normal diet; Basic, normal, high dosage group: animal changes the food normal diet, and the dosage that is tried thing simultaneously is respectively 300mg/kgd, 150mg/kgd and 75mg/kgd.The result shows: extract of picrorhiza iridoid glycoside can obviously reduce cholesterol and the triglyceride in the serum, effectively alleviates the fatty liver degeneration that high lipid food causes, improves the liver function injury that causes because of steatosis.
Observation index:
The a body weight is weighed in the time of 0,30,60,90 days in experiment respectively
B blood biochemistry checking serum AIT AST serum total cholesterol, triglyceride
The c pathological examination: paraffin section, fatty liver and inflammation degree of necrosis are observed in HE dyeing.
The variation of blood fat in each experimental group animal serum of table 1
| Blood fat | Time | The normal control group | Non-processed group | Model control group | Low dose group | Middle dosage group | High dose group |
| Triglyceride (mmol/L) | ?0 ?60d ?90d | ?0.70±0.26 ?0.71±0.21 ?0.62±0.15 | ?0.69±0.31 ?1.41±0.30 ?1.29±0.24 | ?0.72±0.30 ?1.40±0.42 ?1.66±0.28 | ?0.70±0.23 ?1.13±0.32 ?1.00±0.25 | ?0.75±0.28 ?1.10±0.18 ?0.72±0.19 | ?0.75±0.21 ?1.25±0.40 ?0.80±0.16 |
| Cholesterol (mmol/L) | ?0 ?60d ?90d | ?1.36±0.18 ?1.28±0.11 ?1.29±0.19 | ?1.36±0.22 ?2.94±0.57 ?2.47±0.40 | ?1.36±0.21 ?2.85±1.00 ?2.59±0.26 | ?1.45±0.30 ?3.02±1.07 ?2.36±0.25 | ?1.44±0.21 ?3.01±1.02 ?1.31±0.21 | ?1.42±0.21 ?3.07±0.05 ?1.28±0.18 |
The degree of each experimental group animal livers steatosis of table 2
| ?n | Normally | Slightly | Moderate | Severe | |
| ??n??????％ | ????n????％ | ??n????％ | ????n????％ | ||
| Dosage group high dose group model control group in the non-processed group low dose group of normal control group | ?10 ?10 ?10 ?9 ?10 ?9 | ??10?????100 ??0??????0 ??0??????0 ??2??????22.2 ??3??????30 ??0??????0 | ????0????0 ????1????10 ????4????40 ????5????55.6 ????7????70 ????0????0 | ??0????0 ??5????50 ??5????50 ??2????22.2 ??0????0 ??4????44.4 | ????0????0 ????4????40 ????1????10 ????0????0 ????0????0 ????5????55.6 |
The variation of each experimental group animal serum transaminase content of table 3
The preventive and therapeutic effect of the rat fat liver that embodiment 2 extract of picrorhiza iridoid glycoside cause ethanol and high lipid food
| Project | Time | The normal control group | Non-processed group | Model control group | Low dose group | Middle dosage group | High dose group |
| ALT | ?0 ?60d ?90d | ?57.9±7.3 ?55.4±6.3 ?57.0±6.6 | ?58.8±18.6 ?53.5±12.9 ?72.5±12.1 | ?52.2±6.6 ?54.4±8.5 ?103.7±37 | ?55.5±9.9 ?55.6±11.5 ?50.8±22.4 | ?56.9±7.9 ?50.9±20.1 ?58.0±10.9 | ?55.6±6.8 ?52.3±8.0 ?55.2±7.4 |
| AST | ?0 ?60d ?90d | ?203.9±33 ?201.2±39 ?201.6±28 | ?200.8±31 ?216.6±31 ?231.9±41 | ?203.3±23 ?217.3±46 ?253±41.6 | ?205.6±25.8 ?219.3±41.6 ?218.8±49 | ?200.7±24.1 ?217.6±23.1 ?211.1±29.9 | ?208.7±25.5 ?213.5±38.8 ?210.2±24.6 |
60 of rats, male and female half and half, body weight 155 ± 20g is divided into 6 groups, and the high, medium and low dosage of extract of picrorhiza iridoid glycoside is 300mg/kg, 150mg/kg and 75mg/kg for 3 groups.Positive control drug DONGBAO GANTAI group (medicated powder 1g/kg), model group and normal control group (waiting the capacity solvent), beginning in the 1st day, except that the normal control group, all give 30%EtOH10ml/kg, qd, continuous 30 days, feed high lipid food every day simultaneously, change after 30 days and feed normal diet, subsequently by above-mentioned administration grouping scheme.Successive administration 30 days (model and normal control group give equivalent 1%CMC solution).The result shows, the extract of picrorhiza iridoid glycoside HDL-C content that can obviously raise reduces T-CH and TG content.Administration treated animal liver denaturation degrees all alleviates than model group is obvious.Table 4 extract of picrorhiza iridoid glycoside is to the preventive and therapeutic effect of fatty liver rat due to ethanol and the high lipid food
| Group | Dosage (mg/kg) | ??T-ch(mmol/L) | ??TG(mmol/L) | ????HDL-C(mmol/L) | |
| Model group | ???- | ??1.63±0.11 | ??1.05±0.18 | ????0.77±0.14 | |
| The normal control group | ???- | ??1.26±0.14 | ??0.75±0.15 | ????1.02±0.12 | |
| Extract of picrorhiza iridoid glycoside | High | ???300 | ??1.26±0.12 | ??0.64±0.22 | ????1.20±0.13 |
| In | ???150 | ??1.40±0.09 | ??0.70±0.20 | ????1.13±0.15 | |
| Low | ???75 | ??1.49±0.09 | ??0.80±0.24 | ????1.02±0.11 | |
| DONGBAO GANTAI | ???1000 | ??1.49±0.16 | ??0.79±0.24 | ????1.11±0.17 | |
Claims (4)
1, the application of Rhizoma Picrorhizae in lipotropic medicine can be that independent Rhizoma Picrorhizae is made raw material in the medicine, also can be that Rhizoma Picrorhizae and other drug are prepared into compound preparation.
2, according to the medicine of claim 1 exploitation, it is characterized in that medicine is peroral dosage form and the injection type that contains an amount of pharmaceutic adjuvant.
3, the application of extract of picrorhiza iridoid glycoside (bitter glycoside I of Rhizoma Picrorhizae and the bitter glycoside IIHPLC of Rhizoma Picrorhizae content amount to 〉=20%) in control fatty liver medicine, can be that independent extract of picrorhiza iridoid glycoside is made raw material in the medicine, also can be that extract of picrorhiza iridoid glycoside and other drug are prepared into compound preparation.
4, according to the medicine of claim 3 exploitation, it is characterized in that medicine is peroral dosage form and the injection type that contains an amount of pharmaceutic adjuvant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02113737 CN1457794A (en) | 2002-05-15 | 2002-05-15 | New use of picrorhiza rhizome and its iridoid glycoside extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02113737 CN1457794A (en) | 2002-05-15 | 2002-05-15 | New use of picrorhiza rhizome and its iridoid glycoside extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1457794A true CN1457794A (en) | 2003-11-26 |
Family
ID=29426431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02113737 Pending CN1457794A (en) | 2002-05-15 | 2002-05-15 | New use of picrorhiza rhizome and its iridoid glycoside extract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1457794A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102462772A (en) * | 2010-11-15 | 2012-05-23 | 天津药物研究院 | Application of extract of total glucosides of picrorhiza in preparing medicines for preventing and treating fatty liver |
| CN102920831A (en) * | 2012-11-20 | 2013-02-13 | 济南康众医药科技开发有限公司 | Preparation method of rhizoma picrorhizae total saponins |
| CN104402950A (en) * | 2014-12-29 | 2015-03-11 | 济南东源生物医药技术有限公司 | Preparation method of kutkin I crystal |
| CN104906083A (en) * | 2014-06-26 | 2015-09-16 | 西南交通大学 | New use of iridoid compound |
-
2002
- 2002-05-15 CN CN 02113737 patent/CN1457794A/en active Pending
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102462772A (en) * | 2010-11-15 | 2012-05-23 | 天津药物研究院 | Application of extract of total glucosides of picrorhiza in preparing medicines for preventing and treating fatty liver |
| CN102462772B (en) * | 2010-11-15 | 2014-03-12 | 天津药物研究院 | Application of extract of total glucosides of picrorhiza in preparing medicines for preventing and treating fatty liver |
| CN102920831A (en) * | 2012-11-20 | 2013-02-13 | 济南康众医药科技开发有限公司 | Preparation method of rhizoma picrorhizae total saponins |
| CN102920831B (en) * | 2012-11-20 | 2014-07-23 | 济南康众医药科技开发有限公司 | Preparation method of rhizoma picrorhizae total saponins |
| CN104906083A (en) * | 2014-06-26 | 2015-09-16 | 西南交通大学 | New use of iridoid compound |
| CN104906083B (en) * | 2014-06-26 | 2017-08-04 | 西南交通大学 | The new application of iridoid |
| CN104402950A (en) * | 2014-12-29 | 2015-03-11 | 济南东源生物医药技术有限公司 | Preparation method of kutkin I crystal |
| CN104402950B (en) * | 2014-12-29 | 2017-06-16 | 济南东源生物医药技术有限公司 | A kind of picroside Ⅰ crystallization preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chrubasik et al. | A comprehensive review on nettle effect and efficacy profiles, Part I: Herba urticae | |
| Venkatesh et al. | Antihyperglycemic activity of Caralluma attenuata | |
| CN101264122B (en) | Hypericum extract, its making method and medicinal composition and use for treating diabetes | |
| CN1398838A (en) | Diphenylethylene compound and its prepn and application in preventing and treating diabetes | |
| CN101933973B (en) | Medicament composition for preventing and treating liver damage | |
| CN1457794A (en) | New use of picrorhiza rhizome and its iridoid glycoside extract | |
| CN108143755A (en) | A kind of common four-o'clock root extractive of general flavone for preventing diabetes B and its complication, and preparation method and application | |
| CN108586626B (en) | Preparation method and application of tetrastigma hemsleyanum Diels et Gilg oligosaccharide | |
| Singh et al. | Management of diabetes mellitus and its complications by Lodhra: A review | |
| CN102626477B (en) | Externally used traditional Chinese medicine combination for treating long-time traumatic injury | |
| CN100350966C (en) | Chinese medicinal preparation for treating gynecopathy inflammation and its preparing process | |
| CN101147749A (en) | Divaricate velvetplant medicinal preparation for treating diabetes | |
| CN1907432A (en) | Application of polysaccharide from the Gastrodia elata Blume in health caring stuff and medicine | |
| CN100488498C (en) | Application of turmeric extract in preparation of medicine for preventing and postponing chronic kidney function failure | |
| CN108379495B (en) | Application of galangal extract in preparation of preparation for preventing and/or treating non-alcoholic fatty liver disease | |
| CN1293873C (en) | Andrographis herb prepn and its prepn process and application in preparing medicine | |
| WO2013138964A1 (en) | Application of iso-daphnetin compound in preparation of anti-diabetic medicines | |
| Sudipta et al. | Evaluation of antidiabetic activity and histological study of Cyperus kyllinga Endl. roots | |
| CN1155399C (en) | Application of pilose gerbera herb in preparing antineoplastic medicine | |
| CN102327369B (en) | Pharmaceutical composition and medicine for treating hepatic injury, and preparation method thereof | |
| Mushtaq et al. | Toxicity studies of Pimpinella anisum in Albino mice | |
| CN111803559B (en) | Eggplant peel composition with blood sugar reducing effect and preparation method and application thereof | |
| CN104274528A (en) | Cassia polyphenol extractive with immunosuppressive activity, and preparation method and application thereof | |
| Abdelrahman | Hepatoprotective activity of ethanolic and ethyl acetate extracts of Sterculia Setigera against carbon tetrachloride induced hepatotoxicity in albino rats | |
| CN114767760B (en) | A composition with liver protecting effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |